CD95-Fc is already in the phase II of clinical trial for GBM treatment, in which the combination of a drug with radiotherapy was compared with stand-alone radiotherapy.38 Strikingly, the study objective of increasing the percentage of patients reaching the 6-month rate of progression-free survival by 100% in the CD95-Fc group was substantially exceeded. Here, FAS is linked to glioblastoma.